Noninvasive indicators of indications for antiviral therapy in HBeAg-negative chronic HBV infection patients with alanine aminotransferase ≤40 U/L

Chunxia LI; Bing DONG; Lulu ZHOU; Dandan REN; Ruiqin ZHANG; He GUO; Guanghua XU; Na LIU

doi:10.3969/j.issn.1001-5256.2021.01.011

Volume 37 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(1): 51-55

PDF( 2131 KB)

Noninvasive indicators of indications for antiviral therapy in HBeAg-negative chronic HBV infection patients with alanine aminotransferase ≤40 U/L

DOI: 10.3969/j.issn.1001-5256.2021.01.011

Department of Infectious Diseases, Affiliated Hospital of Yan'an University, Yan'an, Shaanxi 716000, China

Received Date: 2020-07-06
Accepted Date: 2020-09-07
Published Date: 2021-01-20

Abstract

Abstract

Objective To investigate the noninvasive indicators of indications for antiviral therapy in HBeAg-negative chronic hepatitis B virus (HBV) infection patients with alanine aminotransferase (ALT) ≤40 U/L under the guidance of liver pathology. Methods A retrospective analysis was performed for the clinical data of 377 HBeAg-negative chronic HBV infection patients with ALT ≤40 U/L who were hospitalized in Affiliated Hospital of Yan'an University, from October 2013 to August 2018 and underwent liver biopsy, among whom the patients with inflammatory activity < A2 and fibrosis stage < F2 were enrolled as non-antiviral therapy group(n=266), and the patients with inflammatory activity ≥A2 or fibrosis stage ≥F2 were enrolled as antiviral therapy group(n=111). The chi-square test was used for comparison of categorical data between two groups; the t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; univariate and multivariate binary logistic regression analyses were used to screen out the influencing factors for the initiation of antiviral therapy; the receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic efficiency of each indicator in determining the need for antiviral therapy in HBeAg-negative chronic HBV infection patients with ALT ≤40 U/L. Results Of all 377 patients, 266 (70.6%) did not need antiviral therapy for the time being, and 111 (29.4%) had marked liver damage and thus needed active antiviral therapy. The multivariate analysis showed that liver stiffness measurement (LSM) (odds ratio [HR]=2.003, 95% confidence interval [CI]: 1.647-2.437, P < 0.05), HBsAg (HR=1.563, 95% CI: 1.110-2.200, P < 0.05), HBV DNA (HR=1.519, 95% CI: 1.173-1.966, P < 0.05), and albumin (HR=0.939, 95% CI: 0.884-0.998, P < 0.05) were independent influencing factors for the initiation of antiviral therapy. The ROC curve analysis showed that the area under the ROC curve (AUC) was 0.749 (95% CI: 0.699-0.799) for LSM, 0.642 (95% CI: 0.586-0.699) for HBV DNA, and 0.565 (95% CI: 0.507-0.623) for HBsAg, and the combination of LSM, HBV DNA, and HBsAg had a larger AUC of 0.779 (95% CI: 0.732-0.827). Conclusion The levels of LSM, HBV DNA, and HBsAg have a reference value in determining the initiation of antiviral therapy in HBeAg-negative chronic HBV infection patients with ALT≤40 U/L.
- Hepatitis B Virus,
- Hepatitis B e Antigens,
- Alanine Transaminase,
- Antiviral Treatment

FullText(HTML)

References(22)

References

[1]	LOZANO R, NAGHAVI M, FOREMAN K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128. DOI: 10.1016/S0140-6736(12)61728-0
[2]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 23(12): 1941-1960. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2015.12.002 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002
[3]	PAPATHEODORIDIS G, VLACHOGIANNAKOS I, CHOLONGITAS E, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review[J]. Hepatology, 2016, 63(5): 1481-1492. DOI: 10.1002/hep.28438
[4]	TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology (Baltimore, Md), 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800
[5]	BERSOFF-MATCHA SJ, CAO K, JASON M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: A review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System[J]. Ann Intern Med, 2017, 166(11): 792-798. DOI: 10.7326/M17-0377
[6]	ZHAO DF.Relationship between ALT, AST, HBeAg and serum HBV DNA content in chronic hepatitis B virus carriers[J/CD]. Chin J Clin Lab Sci(Electronic Edition), 2017, 6(1): 11-13. (in Chinese) 赵冬凤. 慢性乙肝病毒携带者ALT、AST及HBeAg与血清HBV DNA含量的关系[J/CD]. 临床检验杂志(电子版), 2017, 6(1): 11-13.
[7]	ZHOU LL, LIU N, LI CX, et al. Current status of the diagnosis and treatment of chronic hepatitis B virus infection with immune control[J]. J Clin Hepatol, 2020, 36(5): 1134-1137. (in Chinese). DOI: 10.3969/j.issn.1001-5256.2020.05.041 周路路, 刘娜, 李春霞, 等. 慢性HBV感染免疫控制期的抗病毒治疗[J]. 临床肝胆病杂志, 2020, 36(5): 1134-1137. DOI: 10.3969/j.issn.1001-5256.2020.05.041
[8]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
[9]	LI Q, CHEN L, ZHOU Y. Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels[J]. Sci Rep, 2018, 8(1): 5224. DOI: 10.1038/s41598-018-23646-2
[10]	BRAVO AA, SHETH SG, CHOPRA S. Liver biopsy[J]. N Engl J Med, 2001, 344(7): 495-500. DOI: 10.1056/NEJM200102153440706
[11]	BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology, 1996, 24(2): 289-293. DOI: 10.1002/hep.510240201
[12]	CASTERA L, FORNS X, ALBERTI A. Non-invasive evaluation of liver fibrosis using transient elastography[J]. J Hepatol, 2008, 48(5): 835-847. DOI: 10.1016/j.jhep.2008.02.008
[13]	ZHAO Y, LI YE, QI L, et al. Antiviral curative effects of tenofovir and entecavir in treatment of aged patients with chronic hepatitis B and their regulation on inflammation factors[J]. J Jilin Univ(Med Edit), 2019, 45(1): 117-122. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201901022.htm 赵阳, 李烨, 齐玲, 等. 替诺福韦酯和恩替卡韦治疗老年慢性乙型肝炎患者的抗病毒疗效及对致炎细胞因子的调节作用[J]. 吉林大学学报(医学版), 2019, 45(1): 117-122. https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB201901022.htm
[14]	LIM SG. Influencing factors of initiation and timing of discontinuation of treatment for chronic hepatitis B[J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2019, 13(6):528.(in Chinese) Seng-Gee LIM. 慢性乙型肝炎治疗开始和停药时机的影响因素[J/CD]. 中华实验和临床感染病杂志(电子版), 2019, 13(6): 528.
[15]	DOU XG.Anti-virus treatment strategies for chronic hepatitis B virus infection with normal alanine aminotransferase[J]. Chin J Pract Intern Med, 2013, 33(6): 454-456. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201306014.htm 窦晓光. 丙氨酸转氨酶正常的慢性乙型肝炎病毒感染人群抗病毒治疗策略[J]. 中国实用内科杂志, 2013, 33(6): 454-456. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201306014.htm
[16]	KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134(5): 1376-1384. DOI: 10.1053/j.gastro.2008.02.075
[17]	WANG H, RU GQ, YAN R, et al. Histologic disease in chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels[J]. J Clin Gastroenterol, 2016, 50(9): 790-796. DOI: 10.1097/MCG.0000000000000544
[18]	BAI XX, DONG B, GAO HY, et al. Clinical features of immune escape phase and immune control phase of chronic HBV infection[J]. J Clin Hepatol, 2018, 34(12): 2568-2571. (in Chinese) DOI: 10.3969/j.issn.1001－5256.2018.12.012 白萧萧, 东冰, 高红艳, 等. 慢性HBV感染者免疫逃逸期与免疫控制期的临床特征分析[J]. 临床肝胆病杂志, 2018, 34(12): 2568-2571. DOI: 10.3969/j.issn.1001－5256.2018.12.012
[19]	LIU WR, TIAN MX, JIN L, et al. High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads[J]. Ann Surg Oncol, 2015, 22(3): 843-850. DOI: 10.1245/s10434-014-4043-5
[20]	TSENG T C, LIU C J, YANG H C, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load[J]. Gastroenterology, 2012, 142(5): 1140-1149. DOI: 10.1053/j.gastro.2012.02.007
[21]	CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311
[22]	NAKAZAWA T, SHIBUYA A, TAKEUCHI A, et al. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels[J]. J Viral Hepat, 2011, 18(7): e191-e199. http://www.ncbi.nlm.nih.gov/pubmed/21692932/

Relative Articles

[1]	Changxu LI, Xuemin LI, Zhanqiang LIANG, Xibin DUAN, Pengsheng YANG. Application of indocyanine green fluorescence navigation in laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in elderly patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2023, 39(4): 885-891. doi: 10.3969/j.issn.1001-5256.2023.04.020
[2]	Xuelian PENG, Xiaoqing XU, Qin CAO. Clinical efficacy and safety of Danshu Capsule in treatment of chronic cholecystitis and gallstones[J]. Journal of Clinical Hepatology, 2022, 38(9): 2084-2090. doi: 10.3969/j.issn.1001-5256.2022.09.025
[3]	Zhao GuoPing, Hu JianPing, Wang JiRong, Zhang Ming. Experience in laparoscopic cholecystectomy in treatment of acute calculous cholecystitis: a clinical analysis of 86 cases[J]. Journal of Clinical Hepatology, 2018, 34(3): 517-520. doi: 10.3969/j.issn.1001-5256.2018.03.013
[4]	Xi GuangLi, Dong Hao. Clinical effect of laparoscopic cholecystectomy and prognostic analysis in patients with acute cholecystitis[J]. Journal of Clinical Hepatology, 2018, 34(2): 332-336. doi: 10.3969/j.issn.1001-5256.2018.02.022
[5]	Li ZhenLi, Yang Tian. Diagnosis and surgical treatment of xanthogranulomatous cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(2): 247-252. doi: 10.3969/j.issn.1001-5256.2017.02.007
[6]	Zhang JingZhe, Yu Kui. Integrated traditional Chinese and Western medicine therapy for acute and chronic cholecystitis[J]. Journal of Clinical Hepatology, 2017, 33(5): 838-842. doi: 10.3969/j.issn.1001-5256.2017.05.009
[7]	Zhao Bin, Qing XiaoSong, Lai Zhao. Clinical effect of laparoscopic versus open cholecystectomy in treatment of patients with portal hypertension complicated by gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 888-891. doi: 10.3969/j.issn.1001-5256.2017.05.019
[8]	Tan ZhanHai, Zhu GuangHui, Chen JianRong, Zhou LianMing, Yang Zhi, Zhang JiFa, Zhang XueLi, Dan YuanZhou. Clinical effect of laparoscopic cholecystectomy combined with laparoscopic choledocholithotomy T-tube drainage in treatment of gallbladder and common bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(5): 883-887. doi: 10.3969/j.issn.1001-5256.2017.05.018
[9]	Zhao HongGuang, Liu Kai, Liu YaHui. The most appropriate timing for selective laparoscopic cholecystectomy after percutaneous transhepatic gallbladder drainage in patients with acute severe cholecystitis aged above 60 years[J]. Journal of Clinical Hepatology, 2017, 33(4): 705-710. doi: 10.3969/j.issn.1001-5256.2017.04.021
[10]	Yang YaLin, Xu ZhiJie. Postoperative infection in laparoscopic cholecystectomy in treatment of acute cholecystitis complicated by choleperitonitis[J]. Journal of Clinical Hepatology, 2017, 33(1): 98-101. doi: 10.3969/j.issn.1001-5256.2017.01.021
[11]	Chen LuBin, Lu: XiaoHui, Guo Xin. Diagnosis,treatment,and outcome of Mirizzi syndrome in the perioperative period of laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2016, 32(7): 1354-1356. doi: 10.3969/j.issn.1001-5256.2016.07.030
[12]	Ran JiangLin, Zhang ShaoMao, Wen Qiang. Effects of laparoscopic retrograde cholecystectomy versus partial cholecystectomy in treatment of complex bile duct diseases: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 750-753. doi: 10.3969/j.issn.1001-5256.2016.04.030
[13]	Zhou JingSong, Pu DongLi, Du ZiYou. Clinical effects of laparoscopy and laparotomy in treatment of gangrenous cholecystitis[J]. Journal of Clinical Hepatology, 2016, 32(5): 914-917. doi: 10.3969/j.issn.1001-5256.2016.05.021
[14]	Fan Hua, Zhang ShengJun. Comparison of efficacy between choledochoscopic gallbladder-preserving cholelithotomy and laparoscopic cholecystectomy in treatment of gallstones: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1665-1670. doi: 10.3969/j.issn.1001-5256.2015.10.026
[15]	Wang WeiHua. Clinical efficacy of percutaneous transhepatic cholecystostomy combined with laparoscopic cholecystectomy for elderly patients with severe calculous cholecystitis[J]. Journal of Clinical Hepatology, 2015, 31(8): 1291-1294. doi: 10.3969/j.issn.1001-5256.2015.08.026
[16]	Liu Chao, Zhang Lei. Clinical efficacy of transumbilical single-port laparoscopic cholecystectomy in treatment of acute cholecystitis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1678-1681. doi: 10.3969/j.issn.1001-5256.2015.10.029
[17]	Dai JunTao, Zhang Ping, Wang Qing, Shen BoMing. Laparoscopic cholecystectomy for acute cholecystitis: clinical analysis of 216 cases[J]. Journal of Clinical Hepatology, 2014, 30(7): 647-649. doi: 10.3969/j.issn.1001-5256.2014.07.018
[18]	Xu DaHua. Evolution and current challenges of laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2013, 29(3): 166-168.
[19]	Yi ZhengHui, Wang DaQing, Chang YingBin. Surgical experience of laparoscopic cholecystectomy in 53 cases of acute cholecystitis [J]. Journal of Clinical Hepatology, 2013, 29(3): 194-195.
[20]	Xi RuGuang, Zhang ShaoGuang, Yang WanHong, Ding YanZhen. The application of intraoperative cholangiography in laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2011, 27(3): 300-301.

Supplements(0)

Cited By

Cited by

Periodical cited type(31)

1.	丁辉，苏雪梅，张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 .
2.	王慧敏，谭炳芹，王万鹏，吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 .
3.	张璨，张欢欢，高飞，任佩佩，罗明阳，闫冬，王馨，王莹莹，曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 .
4.	李述美，刘冰，刘仁伟，杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 .
5.	安薪宇，乔杰，胡灵溪，王荣琦，南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 .
6.	张航，刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . 本站查看
7.	马杨青，范海纳，孙鑫，刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . 本站查看
8.	张欢，雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 .
9.	陈腾千，姜丽华，张生君，蒋义贵，罗佳，胡永敏，尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 .
10.	李雨蓉，姚明解，王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 .
11.	刘燕娜，姚明解，郑素军，陈香梅，刘向祎，胡鹏，欧启水，窦晓光，陈红松，段钟平，侯金林，南月敏，高志良，徐小元，庄辉，鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 .
12.	裴倩云，孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 .
13.	王鹏飞，刘树红，钱相君，翟相威，文夏杰，姚明解，赵景民，鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 .
14.	郑伟明，罗翠转，卢金英，骆晓豪，刘浩，梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 .
15.	庄云英，张海燕，曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 .
16.	刘燕娜，姚明解，鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 .
17.	Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 .
18.	罗双艳，何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 .
19.	高伟，高虹，尹春梅，杨森林，范晓红，刘春亮，李雪卿，贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 .
20.	王一奇，苑喜微，李冬冬，汤玉会，薛宁宁，崔璐瑶，刘领弟，南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 .
21.	张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 .
22.	刘沁雨，常越，张青，丁玉平，李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 .
23.	翟相威，刘树红，姚明解，钱相君，文夏杰，许强，赵景民，鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 .
24.	范旭，单珊，刘立伟，贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 .
25.	范旭，单珊，刘立伟，贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 .
26.	刘沁雨，常越，张文，张青，卢诚震，李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 .
27.	马玲玉，甄一宁，罗云萍，段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 .
28.	刘沁雨，常越，张青，丁玉平，李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 .
29.	李佳娜，郑瑞琦，李娜，胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . 本站查看
30.	王春艳，纪冬，马丽君，陈松海，王晶晶，邵清，陈国凤，韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 .
31.	宋莹，李世朋，焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 .

Other cited types(12)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (828) PDF downloads(93)

Noninvasive indicators of indications for antiviral therapy in HBeAg-negative chronic HBV infection patients with alanine aminotransferase ≤40 U/L

DOI: 10.3969/j.issn.1001-5256.2021.01.011